Abderrahim Fandi becomes CMO at Oxford BioTherapeutics

Company: Oxford BioTherapeutics Ltd

Appointee: Abderrahim Fandi


United Kingdom

Oxford BioTherapeutics Ltd has recruited Abderrahim Fandi to the newly created position of chief medical officer to help it initiate clinical development in the US of an  antibody-drug conjugate for cancer. He joins from Celgene Corp where he led the development of several oncology compounds as well as managed the company’s epigenetic programme.

Dr Fandi has also held positions at Novartis, Bristol-Myers Squibb Co, AstraZeneca Plc and Sanofi SA. He is a medical doctor and medical oncologist and received a PhD in experimental paediatric medicine from the University of Turin in Italy.

Oxford BioTherapeutics announced the appointment on 1 March 2018.

Copyright 2018 Evernow Publishing Ltd